Skip to main content
Caplight Logo









Cantabio Pharmaceuticals

Cantabio Pharmaceuticals

Private
Palo Alto, CaliforniaHealthcare & Life Scienceshttps://cantabio.com/

Last Round

Grant

Feb 6, 2024

Total Funding Raised

$600,000

Company Overview

Cantabio Pharmaceuticals is a biotechnology company that develops novel disease-modifying therapeutics and diagnostics for neurodegenerative and metabolic conditions such as Parkinson's and Alzheimer's disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

drug discoverybiotechnologyneurodegenerative diseasesmall-molecule therapeuticsprotein misfoldingoxidative stresscomputer-aided drug designCADDpreclinical researchdrug discovery platformprotein stabilizationbiotech startupin silico drug discoverymolecular dynamicstherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cantabio Pharmaceuticals Comparables

Compare Cantabio Pharmaceuticals with similar companies based on industry and business-model similarity.

Cantabio Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Origami Therapeutics
87%
Amathus Therapeutics
85%
Retromer Therapeutics
82%

Cantabio Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 6, 2024
GrantAug 17, 2023
GrantSep 2, 2020
Convertible DebtFeb 2, 2017
Private PlacementOct 21, 2015

Cantabio Pharmaceuticals Investors

Notable investors and investment history

Cantabio Pharmaceuticals investors
InvestorRounds
The Michael J. Fox Foundation for Parkinson's ResearchGrant
Yorkville AdvisorsConvertible Debt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 24, 2026

    Monthly visitors increased 48% MoM, reaching 2.1K.

  • Jan 25, 2026

    Monthly visitors grew 64% MoM, reaching 1.2K.

Cantabio Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cantabio Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cantabio Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersPalo Alto, California
Employee Range13
Year Founded2009
Last FundingFeb 6, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?